SearchNewsletters
Logo
HomeLatestBusiness NewsMoney & MarketsTech & InnovationA.I.LifestyleLeadership✉️ Emails🎧 Podcasts
Logo
FacebookXInstagramYoutubeRSS Feed
SitemapAboutAccessibilityPrivacyTerms of ServiceAdvertising
© 2026 Quartz Media Network. All Rights Reserved.
Markets

How major US stock indexes fared Tuesday, 2/27/2024

Stocks held relatively steady on Wall Street near their record levels

ByThe Associated Press and AP News
Share to XShare to FacebookShare to RedditShare to EmailShare to Link
Add Quartz on Google
Share to XShare to FacebookShare to RedditShare to EmailShare to Link

Stocks held relatively steady on Wall Street near their record levels.

The S&P 500 managed a gain of 0.2% Tuesday. The Dow Jones Industrial Average fell 0.2%, and the Nasdaq $NDAQ composite rose 0.4%.

Macy’s rose after unveiling a restructuring plan, and Norwegian Cruise Line $NCLH steamed higher on hopes for a stronger 2024. Chevron $CVX weighed on the Dow amid worries that its pending takeover of Hess may be facing a threat. Treasury yields were mixed in the bond market after a report showed that confidence among U.S. consumers unexpectedly weakened. The yield on the 10-year Treasury edged up to 4.31%

On Tuesday:

The S&P 500 rose 8.65 points, or 0.2%, to 5,078.18.

The Dow Jones Industrial Average fell 96.82 points, or 0.2%, to 38,972.41.

The Nasdaq composite rose 59.05 points, or 0.4%, to 16,035.30.

The Russell 2000 index of smaller companies rose 27.14 points, or 1.3%, to 2,056.11.

For the week:

The S&P 500 is down 10.62 points, or 0.2%.

The Dow is down 159.12 points, or 0.4%.

The Nasdaq is up 38.48 points, or 0.2%.

The Russell 2000 is up 39.42 points, or 2%.

For the year:

The S&P 500 is up 308.35 points, or 6.5%.

The Dow is up 1,282.87 points, or 3.4%.

The Nasdaq is up 1,023.95 points, or 6.8%.

The Russell 2000 is up 29.03 points, or 1.4%.

📬 Sign up for the Daily Brief

Our free, fast and fun briefing on the global economy, delivered every weekday morning.

Related Content

Trump drops the Hormuz shipping fee but presses ahead with the Iran blockade
Biogen stock sinks after Alzheimer's drug trial data fails to impress investors